Apex Physical Medicine and Rehabilitation Professional LLC
Apex Physical Medicine and Rehabilitation Professional LLC was paid $1.38M by Medicaid between Oct 2020 and Oct 2024, across 53 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 78% of everything it billed.
COLORADO SPRINGS, CO 80917
Next to other Clinical Medical Laboratory providers in Colorado
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,561 | $56K | |
| 2021 | 1,543 | $27K | |
| 2022 | 590 | $63K | |
| 2023 | 9,016 | $478K | |
| 2024incomplete | 21,257 | $752K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 78% | 6,895 | 5,848 | $1.07M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 15% | 6,246 | 5,380 | $208K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 456 | 361 | $37K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.1% | 12,089 | 5,645 | $16K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 456 | 361 | $9K |
| 83992 | <1% | 88 | 77 | $2K | |
| 80364 | <1% | 88 | 77 | $1K | |
| 80373 | <1% | 88 | 77 | $1K | |
| 80348 | <1% | 88 | 77 | $1K | |
| 80336 | <1% | 88 | 77 | $1K | |
| 80323 | <1% | 88 | 77 | $1K | |
| 80347 | <1% | 88 | 77 | $1K |
41 more codes
| 80369 | <1% | 88 | $1K | |
| 80372 | <1% | 88 | $1K | |
| 80355 | <1% | 88 | $1K | |
| 80366 | <1% | 88 | $1K | |
| 80365 | <1% | 88 | $1K | |
| 80354 | <1% | 88 | $1K | |
| 80339 | <1% | 88 | $1K | |
| 80368 | <1% | 88 | $1K | |
| 80371 | <1% | 88 | $1K | |
| 80324 | <1% | 88 | $1K | |
| 80333 | <1% | 88 | $1K | |
| 80358 | <1% | 88 | $1K | |
| 80359 | <1% | 88 | $1K | |
| 80349 | <1% | 88 | $1K | |
| 80345 | <1% | 88 | $1K | |
| 96132 | <1% | 185 | $339.17 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 686 | $225.32 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 227 | $136.12 |
| 96136 | <1% | 251 | $128.55 | |
| 96137 | <1% | 312 | $116.55 | |
| 20561 | <1% | 206 | $109.22 | |
| G3002 | Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using g3002, 30 minutes must be met or exceeded.) | <1% | 106 | $98.58 |
| 99439 | <1% | 30 | $97.06 | |
| G3003 | Each additional 15 minutes of chronic pain management and treatment by a physician or other qualified health care professional, per calendar month. (list separately in addition to code for g3002. when using g3003, 15 minutes must be met or exceeded.) | <1% | 107 | $72.04 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 653 | $71.88 |
| 99490 | Ccm add 20min | <1% | 30 | $63.73 |
| 96116 | <1% | 141 | $18.87 | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 16 | $8.16 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 596 | $3.33 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 513 | $0.70 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 0% | 45 | $0.00 |
| 97012 | 0% | 15 | $0.00 | |
| 80363 | 0% | 88 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 234 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 677 | $0.00 |
| J3490 | Unclassified drugs | 0% | 641 | $0.00 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 0% | 19 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 12 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 53 | $0.00 |
| 99205 | Prolong outpt/office vis | 0% | 31 | $0.00 |
| 98943 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Bissell Eye Care, LLC | Bakerstown, PA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.